Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. - Wikidata - awgldk - TriplyDB

Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.

Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.

http://www.wikidata.org/entity/Q34345953

about

Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.Pharmacogenetics and outcome with antipsychotic drugs PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2 Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity Pharmacogenomics of off-target adverse drug reactions.HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis.Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.Real-world efficiency of pharmacogenetic screening for carbamazepine-induced severe cutaneous adverse reactions.HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.Towards the clinical implementation of pharmacogenetics in bipolar disorder.Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches Implementation and utilization of genetic testing in personalized medicine.Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.The uncanny return of the race concept.PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.EHR based Genetic Testing Knowledge Base (iGTKB) Development.Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs.Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges.Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.The HLA-A*31:01 allele: influence on carbamazepine treatment Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing Integrating pharmacogenetic information and clinical decision support into the electronic health record.The emerging era of pharmacogenomics: current successes, future potential, and challenges.Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.Genomic architecture of pharmacological efficacy and adverse events.Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations.Role of dermatology in pharmacogenomics: drug-induced skin injury.The pharmacogenomics of epilepsy.The global spectrum of protein-coding pharmacogenomic diversity.Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review.Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology.Evidence and resources to implement pharmacogenetic knowledge for precision medicine.Integrating pharmacogenomics into electronic health records with clinical decision support.

P2860

Q24567778-79F26B4C-A921-42F0-A1D4-67A3DB6107C2 Q26800980-63311C7B-C465-4A97-A130-942B36325B55 Q26852807-4265FBA8-7BD7-42CD-8622-322CE22C7E8A Q27011622-FCFD033E-8090-442C-9FD0-A1DAF33EC466 Q28079766-3D8F73E7-4EE4-42AC-B8E9-6186B5AC4185 Q28083100-3AE49076-8BF4-4225-A964-97B7B68F1F46 Q30400366-73DA49F5-B330-4DA0-8B34-B096906DFF0A Q30855868-74575426-C94E-4EDD-BEC2-0C9C0AE95BCD Q31058146-C7BAFB24-0868-4536-93DD-AE8A6B320C53 Q33578364-10DE0827-CE57-47AA-9286-154B99BA6484 Q33666857-41475CBB-0442-4362-97FB-FA2101B36D1C Q33688133-81A038E2-82EC-4B16-878A-50FB48B124D0 Q33725390-F2214E08-0212-450D-8A8A-AF9BD995B1A4 Q33839145-CC7771DD-13B1-4CBA-AEEF-0F0D1185B0D2 Q34147916-3154CA41-080D-4A68-82B8-43FDDCA549D2 Q34389432-0816B1E6-081C-46BB-B816-FEB4D242DEB7 Q34408357-8E95F9FA-ED15-4CE0-A9E4-FA86BE1E7F77 Q34448886-640D8030-617F-4C8D-9EAD-0A0F5984B837 Q35168561-4B529D77-D6C5-44A8-883B-1ADA03771559 Q35852441-D75BA5BE-75ED-4C75-AE46-637903A80AA2 Q36166107-2835980D-C03B-48F9-9BD4-20A3F7E7502A Q36398661-011E1485-F1FC-432C-A6D3-80025951E985 Q37344778-D051C497-74AE-4C40-8D45-D537A25779D0 Q37433329-535728E4-3C8E-4100-B5C2-EB5E781E101A Q37612442-B79E0BB2-FEFD-4D7E-BCB3-316B88E34B9B Q37626751-CD722054-5B89-43FD-A274-F196165E0733 Q37652863-725DC2AD-62D9-4590-95F3-F560DF9B2A37 Q37715400-C7BB66B8-894C-4F4E-8915-ECE21769A2A0 Q38200683-BAA16CBB-B1A3-4B42-8767-189CEC0EAA48 Q38217626-4CF0C136-016F-4FF8-B0C2-DEE253778206 Q38292930-028AD67C-495B-4704-85A5-25A9CF8820AB Q38388873-61E41822-F0C7-4AF1-ACC0-ED48C9E25CDA Q38396234-F153A0AD-8422-40B5-B21C-073BE5F4B61B Q38577986-CC53B5FF-0529-4BE1-9ECD-080A14E7CEBD Q38806047-2D063D30-7C0E-4F6A-96EC-1EE85CD94936 Q38983589-2D1B82DB-8501-4129-9F41-482DEB7D2A80 Q39062032-2800E6CC-607B-4993-909F-C2BC591EC0AF Q39103035-6B7B7671-92CA-4778-BCDB-66FDD202A39E Q39173298-C13C0FDD-A5C6-4F23-9E08-CB7579873754 Q39173300-DF9B822E-13FB-4EFA-BC91-42343CA7CEE4

P2860

Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.

http://www.wikidata.org/entity/Q34345953

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Clinical Pharmacogenetics Impl ...... type and carbamazepine dosing.

@ast

Clinical Pharmacogenetics Impl ...... type and carbamazepine dosing.

@en

Clinical Pharmacogenetics Impl ...... type and carbamazepine dosing.

@nl

type

label

Clinical Pharmacogenetics Impl ...... type and carbamazepine dosing.

@ast

Clinical Pharmacogenetics Impl ...... type and carbamazepine dosing.

@en

Clinical Pharmacogenetics Impl ...... type and carbamazepine dosing.

@nl

prefLabel

Clinical Pharmacogenetics Impl ...... type and carbamazepine dosing.

@ast

Clinical Pharmacogenetics Impl ...... type and carbamazepine dosing.

@en

Clinical Pharmacogenetics Impl ...... type and carbamazepine dosing.

@nl

P1433

Q34345953-9E890932-CD6E-4370-9521-10A88D15AC65

P1476

Q34345953-6371476F-7DD1-4A71-A915-6A4D9FF16FD4

P2093

Q34345953-1130DC94-BBB5-4270-968A-B1D1BB5ECF49

Q34345953-127C374F-CA3A-429C-86DA-DE85C881C90E

Q34345953-1D251E69-7355-4CE8-9FAB-31220903A8E6

Q34345953-410167C9-8225-4CA4-A40A-81C4ADCA81B2

Q34345953-5BE84392-5447-4DFF-93DB-F5B12FD60B29

Q34345953-C337080E-6206-4BC2-9F83-6569838026A4

Q34345953-C4DB2D47-60DE-4CE9-8B1E-2487D61C7CC2

Q34345953-DE600551-6EA4-409F-9849-F7426D9F8599

Q34345953-F0507A55-6B15-445F-A5AF-F18DA65B7A80

P2860

Q34345953-01AFFA04-C87C-42B9-9E3C-AD3C715DF163

Q34345953-090679BA-D58E-4205-9575-E51B83E5474D

Q34345953-0AC54245-42A0-4347-9AFA-48C6841FA15C

Q34345953-11881783-21B2-4473-A261-02620FD9CAAA

Q34345953-2D5BCB21-550C-4BD1-B6A8-7CA2405D79BC

Q34345953-31A5E1B0-0EC6-47A8-A20D-D92B440F0A8A

Q34345953-3728DA14-E929-4422-AE78-B59A92496B1F

Q34345953-38F7B0C4-ACE6-4C1D-AC0F-7B8AD567F53C

Q34345953-3AE596BE-8782-4F69-8B16-179C087DBA7D

Q34345953-4FD43650-9A1F-447F-A6ED-FB22B79ECD74

P304

Q34345953-70824E20-E54E-4A0F-A701-C197319BAA3E

P31

Q34345953-B95D04CE-BBA7-4943-8334-1BC8F08DEA47

P356

Q34345953-E2298C37-423C-445C-BF04-4334CD82257B

P407

Q34345953-AF381216-8330-4C89-A223-A03BEBE2DC75

P433

Q34345953-961F19F0-68C8-452D-8AB2-DEE1761BD383

P478

Q34345953-A64FCDCD-6078-4E0C-887A-7683490445D2

P50

Q34345953-11DDD9C1-2476-44D2-A2BA-9B3DEC637311

Q34345953-9E833666-6FD4-4373-836F-F0D0E54B17EC

P577

Q34345953-C988F0B4-DF3D-44A4-8B6D-4B0BCA397A45

P5875

Q34345953-859131EE-E2D0-439C-901D-4354ED7C8EC1

P698

Q34345953-06372F84-9A27-4572-9159-0783CCB137A2

P932

Q34345953-D0B6B5D4-BEE9-422F-AE2F-11212863F198

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Clinical Pharmacogenetics Impl ...... otype and carbamazepine dosing

@en

P2093

A L George

http://www.w3.org/2001/XMLSchema#string

Clinical Pharmacogenetics Implementation Consortium

http://www.w3.org/2001/XMLSchema#string

D J Müller

http://www.w3.org/2001/XMLSchema#string

E Tran

http://www.w3.org/2001/XMLSchema#string

J R Kelsoe

http://www.w3.org/2001/XMLSchema#string

K E Caudle

http://www.w3.org/2001/XMLSchema#string

M Whirl-Carrillo

http://www.w3.org/2001/XMLSchema#string

R Berger

http://www.w3.org/2001/XMLSchema#string

S G Leckband

http://www.w3.org/2001/XMLSchema#string

P2860

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing

Medical genetics: a marker for Stevens-Johnson syndrome

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study.

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans

Severe adverse cutaneous reactions to drugs.

A marker for Stevens-Johnson syndrome ...: ethnicity matters.

P304

324-328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2013.103

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

Munir Pirmohamed

Henry M. Dunnenberger

P577

2013-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236929232

http://www.w3.org/2001/XMLSchema#string

P698

23695185

http://www.w3.org/2001/XMLSchema#string

P932

3748365

http://www.w3.org/2001/XMLSchema#string